We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss
Read MoreHide Full Article
Aduro Biotech, Inc. reported fourth-quarter 2017 loss of 34 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 44 cents.
Quarterly revenues fell 3.1% year over year to $3.8 million, mainly due to a decrease in grant revenues. The top line also missed the Zacks Consensus Estimate of $4 million.
Aduro’s shares have underperformed the industry in a year’s time. The stock has declined 41.4%, comparing unfavorably with the industry’s decrease of 5.3%.
Research and development expenses rose 9.6% in the reported quarter to $22.9 million, mainly due to an increase in costs related to manufacturing of B-select antibodies and higher facility related costs. However, this downside was partially offset by decreased manufacturing costs regarding discontinuation of the company’s pancreatic cancer program.
General and administrative expenses were $8.8 million, up 10% year over year on higher stock-based compensation expense and consulting and professional fees.
2017 Results
While full-year sales tumbled 66.1% year over year to $17.1 million, full-year loss of $1.26 per share was narrower than the year-ago figure of $1.40.
Pipeline Update
Aduro has a broad pipeline of novel immunotherapies being developed for treating a variety of cancers.
The company evaluates its STING pathway activator, ADU-S100, in combination with Novartis AG’s (NVS - Free Report) PD-1 checkpoint inhibitor, PDR001, in a phase Ib trial for treating solid tumors and lymphomas. Additionally, the candidate is being evaluated in a phase I study as a monotherapy on patients with cutaneous accessible metastatic solid tumors or lymphomas. Top-line data from the program is expected soon.
Meanwhile, in December 2017, Aduro announced that it has initiated a phase I/II2 dose escalation study, examining its pipeline candidate, BION-1301, for treatment of adults with relapsed or refractory multiple myeloma.
Aduro Biotech, Inc. Price, Consensus and EPS Surprise
Aduro carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the health care sector are Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Ligand Pharmaceuticals Incorporated (LGND - Free Report) . While Regeneron sports a Zacks Rank #1 (Strong Buy), Ligand carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $17.13 to $18.65 and from $20.37 to $21.56 for 2018 and 2019, respectively, in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 9.15%.
Ligand’s earnings per share estimates have been revised upward from $3.78 to $4.15 for 2018 in the last 30 days. The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24.88%. Share price of the company has surged 50.4% over a year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Aduro (ADRO) Q4 Loss Narrower Than Expected, Revenues Miss
Aduro Biotech, Inc. reported fourth-quarter 2017 loss of 34 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 36 cents and the year-ago loss of 44 cents.
Quarterly revenues fell 3.1% year over year to $3.8 million, mainly due to a decrease in grant revenues. The top line also missed the Zacks Consensus Estimate of $4 million.
Aduro’s shares have underperformed the industry in a year’s time. The stock has declined 41.4%, comparing unfavorably with the industry’s decrease of 5.3%.
Research and development expenses rose 9.6% in the reported quarter to $22.9 million, mainly due to an increase in costs related to manufacturing of B-select antibodies and higher facility related costs. However, this downside was partially offset by decreased manufacturing costs regarding discontinuation of the company’s pancreatic cancer program.
General and administrative expenses were $8.8 million, up 10% year over year on higher stock-based compensation expense and consulting and professional fees.
2017 Results
While full-year sales tumbled 66.1% year over year to $17.1 million, full-year loss of $1.26 per share was narrower than the year-ago figure of $1.40.
Pipeline Update
Aduro has a broad pipeline of novel immunotherapies being developed for treating a variety of cancers.
The company evaluates its STING pathway activator, ADU-S100, in combination with Novartis AG’s (NVS - Free Report) PD-1 checkpoint inhibitor, PDR001, in a phase Ib trial for treating solid tumors and lymphomas. Additionally, the candidate is being evaluated in a phase I study as a monotherapy on patients with cutaneous accessible metastatic solid tumors or lymphomas. Top-line data from the program is expected soon.
Meanwhile, in December 2017, Aduro announced that it has initiated a phase I/II2 dose escalation study, examining its pipeline candidate, BION-1301, for treatment of adults with relapsed or refractory multiple myeloma.
Aduro Biotech, Inc. Price, Consensus and EPS Surprise
Aduro Biotech, Inc. Price, Consensus and EPS Surprise | Aduro Biotech, Inc. Quote
Zacks Rank
Aduro carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the health care sector are Regeneron Pharmaceuticals, Inc. (REGN - Free Report) and Ligand Pharmaceuticals Incorporated (LGND - Free Report) . While Regeneron sports a Zacks Rank #1 (Strong Buy), Ligand carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $17.13 to $18.65 and from $20.37 to $21.56 for 2018 and 2019, respectively, in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 9.15%.
Ligand’s earnings per share estimates have been revised upward from $3.78 to $4.15 for 2018 in the last 30 days. The company delivered a positive surprise in three of the trailing four quarters with an average beat of 24.88%. Share price of the company has surged 50.4% over a year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>